A Novel Actor in Skin Biology: The Mineralocorticoid Receptor

    October 2015 in “ Experimental dermatology
    Nicolette Farman, Van Tuan Nguyen
    TLDR Blocking the mineralocorticoid receptor can help treat skin thinning caused by steroids.
    The study highlighted the role of the mineralocorticoid receptor (MR) in skin biology, particularly its involvement in hair follicle morphogenesis and epidermal homeostasis. Using mouse models, researchers found that MR expression in the skin varied during development and that MR knockout led to increased epidermal thickness and abnormal differentiation marker expression. However, these changes normalized postnatally, suggesting compensatory mechanisms. The study also noted that MR and glucocorticoid receptor (GR) have overlapping but distinct roles in the epidermis. Importantly, MR overactivation by glucocorticoids could contribute to skin atrophy and alopecia, which could be mitigated by MR antagonists like spironolactone and eplerenone. This research proposed that topical MR blockers might limit glucocorticoid-induced skin damage, emphasizing MR's significance in dermato-endocrinology.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    4 / 4 results

      community When someone posts a scalp tension theory

      in Satire  265 upvotes 3 years ago
      Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community Group Buy for MR antagonist finerenone

      in Product  11 upvotes 1 year ago
      User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

    Similar Research

    5 / 401 results